Infliximab antibody | AbD17841_hIgG1

100% Secure


Human anti Infliximab:HRP

Anti-infliximab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for infliximab or biosimilars. It can be used as detection antibody in PK bridging ELISA with HCA212 to measure free drug, and as calibrator in an ADA bridging ELISA.

Human anti Infliximab

Anti-infliximab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for infliximab or biosimilars. It can be used as detection antibody in PK bridging ELISA with HCA212 to measure free drug, and as calibrator in an ADA bridging ELISA.

Product Type
Monoclonal Antibody
Clone
AbD17841_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA213P E 0.1 mg
HCA213 E 0.1 mg
HCA213G E 1 mg
Human Anti-Infliximab, clone AbD17841_hIgG1 is an anti-idiotypic antibody that specifically recognizes the infliximab monoclonal antibody and inhibits the binding of infliximab to its target. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD17841_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD17841_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays.

Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNFα) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.

View a summary of all Anti-Infliximab Antibodies.

Product Details

Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Infliximab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=1.8 nM by real time, label-free molecular interaction analysis on immobilized Infliximab.
Approx. Protein Concentrations
Total protein concentration 0.1 mg/ml
Approx. Protein Concentrations
Pack Size: 0.1 mg
Antibody concentration 0.5 mg/ml
Pack Size: 1 mg
Antibody concentration 1.0 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch.
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Infliximab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 1/100 1/1000
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in as a detection antibody in an Infliximab bridging ELISA together with HCA212 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Human anti Infliximab HCA212 0.1 mg E
Human anti Infliximab HCA214 0.1 mg E
Human anti Infliximab HCA215 0.1 mg E
Human anti Infliximab HCA216 0.1 mg E
Recombinant Human TNF Alpha PHP051 50 µg E FN WB
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Infliximab HCA212 0.1 mg E
Human anti Infliximab HCA214 0.1 mg E
Human anti Infliximab HCA215 0.1 mg E
Human anti Infliximab HCA216 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ
Mouse anti Human IgG (Fc) CH2 Domain:HRP MCA647P 0.2 mg C* E
Recombinant Human TNF Alpha PHP051 50 µg E FN WB

Product Specific References

References for Infliximab antibody

  1. Hernández-Breijo, B. et al. (2015) Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator.
    10th Congress of ECCO, Barcelona P020
  2. Hernández-Breijo, B. et al. (2016) Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
    Biochem Pharmacol. Sep 21. pii: S0006-2952(16)30302-1. [Epub ahead of print]